Ovary, Fallopian Tube and Primary Peritoneal Carcinoma
Histopathology Reporting Guide

Family/Last name

Date of birth DD – MM – YYYY

Given name(s)

Date of request DD – MM – YYYY

Patient identifiers

Accession/Laboratory number

Elements in **black text** are REQUIRED. Elements in **grey text** are RECOMMENDED.

GENETIC STATUS
- BRCA1
- BRCA2
- Lynch syndrome
- Other
- Not known

PRIOR CHEMOTHERAPY
- No chemotherapy administered
- Prior chemotherapy administered
- Not known

SPECIMEN TYPE (select all that apply)
- Right ovary
- Left ovary
- Right ovarian cystectomy
- Left ovarian cystectomy
- Right fallopian tube
- Left fallopian tube
- Uterus
- Cervix
- Omentum
- Peritoneal biopsies
- Peritoneal washings/ascitic fluid
- Lymph nodes (specify site/s)
- Other

MACROSCOPIC TUMOUR SITE (select all that apply)
- Left ovary
- Right ovary
- Left fallopian tube
- Fimbrial
- Non fimbrial
- Right fallopian tube
- Fimbrial
- Non fimbrial
- Peritoneum
- Other (specify)
- Indeterminate

TUMOUR DIMENSIONS

(Note: If separate tumours specify dimensions for each site)

MACROSCOPIC DESCRIPTION OF OMENTUM

Required only if omentum submitted

Omentum dimensions

Omental involvement

Maximum dimension of largest deposit

BLOCK IDENTIFICATION KEY

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)
## Histological Tumour Type

### Epithelial
- Percentage: 
- List subtypes:

### Sarcomatous
- Percentage: 
- Type: Heterologous, Homologous

## Pattern of Invasion
(For mucinous carcinomas only)
- Expansile
- Infiltrative/destructive

## Carcinosarcoma Subtypes

### Tumour Grade

**Note:** If chemotherapy has been administered the grading may need to be based on the pre-chemotherapy biopsy.

- **Serous carcinomas:**
  - Low grade
  - High grade

- **Endometrioid carcinomas:**
  - G1: Well differentiated
  - G2: Moderately differentiated
  - G3: Poorly differentiated
  - GX: Cannot be graded

- **Clear cell carcinomas:**
  - High grade

- **Undifferentiated carcinomas:**
  - High grade

- **Carcinosarcomas:**
  - High grade

- **Mucinous carcinomas:**
  - G1: Well differentiated
  - G2: Moderately differentiated
  - G3: Poorly differentiated
  - GX: Cannot be graded

### Serous Tubal Intraepithelial Carcinoma (STIC)

Required only if fallopian tube(s) are submitted and applicable to high grade serous carcinoma only

- **Right FT**
  - Present - fimbrial
  - Present - non-fimbrial
  - Not identified
  - Cannot be assessed

- **Left FT**
  - Present - fimbrial
  - Present - non-fimbrial
  - Not identified
  - Cannot be assessed

## Tumour Grade (cont.)

**Note:** If chemotherapy has been administered the grading may need to be based on the pre-chemotherapy biopsy.

- **Endometrioid carcinomas:**
  - G1: Well differentiated
  - G2: Moderately differentiated
  - GX: Cannot be graded

- **Clear cell carcinomas:**
  - High grade

- **Undifferentiated carcinomas:**
  - High grade

- **Carcinosarcomas:**
  - High grade

- **Mucinous carcinomas:**
  - G1: Well differentiated
  - G2: Moderately differentiated
  - G3: Poorly differentiated
  - GX: Cannot be graded

### Serous Tubal Intraepithelial Carcinoma (STIC) (cont.)

Required only if fallopian tube(s) are submitted and applicable to high grade serous carcinoma only

- **Right FT**
  - Present - fimbrial
  - Present - non-fimbrial
  - Not identified
  - Cannot be assessed

- **Left FT**
  - Present - fimbrial
  - Present - non-fimbrial
  - Not identified
  - Cannot be assessed

### Histological Sites of Tumour Involvement

- **Right ovary**
  - Not involved
  - Involved
  - Cannot be assessed
  - Not applicable

- **Left ovary**
  - Not involved
  - Involved
  - Cannot be assessed
  - Not applicable

- **Right ovarian capsule/surface**
  - Not involved
  - Involved
  - Cannot be assessed
  - Not applicable

- **Left ovarian capsule/surface**
  - Not involved
  - Involved
  - Cannot be assessed
  - Not applicable

- **Right fallopian tube**
  - Not involved
  - Involved
  - Cannot be assessed
  - Not applicable
### HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT (Cont.)

**Left fallopian tube**
- Involved
- Not involved

**Uterus**
- Not involved
- Involved

**Omentum**
- Not involved
- Involved

**Peritoneum (including uterine serosa)**
- Not involved
- Involved

**Other involved organs(s)/sites(s) (specify)**

### LYMPH NODE STATUS (cont.)

**Regional**
- Right pelvic
  - Number of lymph nodes examined**
  - Number of positive lymph nodes**

- Para-aortic
  - Number of lymph nodes examined**
  - Number of positive lymph nodes**

**Non-regional**
- Region:
  - Pelvis (specify site(s))
  - Abdomen (specify site(s))

**COEXISTENT PATHOLOGY**
- Endometriosis (specify sites)
- Other (specify)

**ANCILLARY STUDIES**
- Immunohistochemical markers
- Molecular data
PROVISIONAL PATHOLOGICAL STAGING PRE-MDTM

FIGO (2014 edition) (Copyright permission pending.)

Site of primary tumour
- Primary tumour, ovary (OV)
- Primary tumour, fallopian tube (FT)
- Primary tumour, peritoneum (P)
- Undesignated: site of primary tumour cannot be assessed (X)

Stage
- I  Tumour is confined to ovaries or fallopian tube(s)
  - IA  Tumour limited to 1 ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - IB  Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - IC  Tumour limited to 1 or both ovaries or fallopian tubes, with any of the following:
    - IC1  Surgical spill
    - IC2  Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
    - IC3  Malignant cells in the ascites or peritoneal washings

- II  Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
  - IIA  Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
  - IIB  Extension to other pelvic intraperitoneal tissues

- III  Tumour involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
  - IIIA1  Positive retroperitoneal lymph nodes only (cytologically or histologically proven):
    - IIIA1(i)  Metastasis up to 10mm in greatest dimension
    - IIIA1(ii)  Metastasis more than 10mm in greatest dimension
  - IIIA2  Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
  - IIIB  Macroscopic peritoneal metastasis beyond the pelvis up to 2cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes
  - IIIC  Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)

- IV  Distant metastasis excluding peritoneal metastases
  - IVA  Pleural effusion with positive cytology
  - IVB  Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)